BrightEdge is the innovation, impact investment and venture capital arm of the American Cancer Society. Today, our donor-funded ACS Impact Venture Fund (AIVF) invests in for-profit, early-stage companies developing cutting-edge, cancer-focused therapeutics, diagnostics, devices, and technologies to fuel and accelerate ACS’s mission of ending cancer as we know it, for everyone.
13
Total Investments
8
Portfolio Companies
-
Exits
2
Industries
General Information
Industries
Finance, Financial Services
Funding Stage
Seed +2
Company Overview
Investment Criteria
Investment Thesis
•••••• •••••• ••••••
About BrightEdge Ventures
Recent Investments (13)
View All| Company | Stage | Amount | Date |
|---|---|---|---|
| Series B | •••••• | Sep 2025 | |
| Series B | •••••• | May 2025 | |
| Late Vc | •••••• | Feb 2024 | |
| Series A | •••••• | Apr 2023 | |
| Series A | •••••• | Nov 2022 | |
•••• ••••
|
Seed | •••••• | Oct 2022 |
|
•••• ••••
|
Seed | •••••• | Jul 2022 |
|
•••• ••••
|
Acquisition | •••••• | Feb 2022 |
|
•••• ••••
|
Series D | •••••• | Dec 2021 |
|
•••• ••••
|
Series A | •••••• | Nov 2021 |
All startup & investor data, one platform.
Filter investors by stage, sector, and geography. Compare portfolios side by side. Spot market signals before anyone else.
